Advanced Filters
noise

Junggu, Korea, Republic of Clinical Trials

A listing of Junggu, Korea, Republic of clinical trials actively recruiting patients volunteers.

Found 1,032 clinical trials
H Hwoon-Yong Jung, Ph.D

Efficacy and Safety of EsoDuo®

Clinical Trial to Evaluate the Effects of EsoDuo® in Controlling Reflux Symptoms Related to the Acid

19 years of age All Phase 4

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.

18 - 99 years of age All Phase 1

Safety and Efficacy of AR1005 in Patients with Lewy Body Disease

This study is a phase 2a, single-center, double-blind and randomized clinical trial that evaluates the safety and efficacy of AR1005 administration in 60 patients with cognitive impairment due to Lewy body disease. The study evaluates whether the administration of AR1005 in patients with cognitive impairment due to Lewy body disease …

60 years of age All Phase 2
H Hojin Lee, MD, PhD

Intrathecal Morphine Injection Versus Continuous Wound Infiltration After Pancreaticoduodenectomy

This is a prospective randomized open-label noninferiority trial that compares intrathecal morphine injection and continuous wound infiltration after open pancreaticoduodenectomy.

19 years of age All Phase N/A
G Geunhwa Choi, Bachelor's degree

Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity

Chronic graft-versus-host disease (cGVHD) is a complication that occurs in 30-40% of recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and is a major cause of late non-relapse mortality. In cases where the initial treatment response is inadequate, irreversible tissue damage often persists, making it a fatal complication that significantly …

19 years of age All Phase 2
I InKeun Park, M.D, Ph D

Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

This is a phase 2 single-arm, open-label clinical trial designed to evaluate the efficacy and safety of tarlatamab in patients with relapsed extrapulmonary neuroendocrine carcinoma (EPNEC) who have previously received platinum-based first-line chemotherapy. Participants will receive tarlatamab on Cycle 1 Day 1 (C1D1), Day 8 (C1D8), and Day 15 (C1D15), …

19 years of age All Phase 2

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

18 years of age All Phase 2
J Ja Min Byun, MD

NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL

An Open, Single treatment arm, Multi-center, Prospective, Phase 2 Trial to Evaluate Efficacy and Safety of NB02 (Poseltinib) combined with Rituximab and Lenalidomide as a Salvage Therapy for Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

19 - 80 years of age All Phase 2

Clinical Study for the Evaluation of Safety and Tolerability of NCP112 Eye Drops

The objective is to evaluate the safety, local tolerability, and pharmacokinetics of NCP112 eye drops through single and multiple dose-escalation ocular administrations in healthy adults.

19 - 50 years of age All Phase 1
Y Young-Eun Jang, MD, PhD

Deep Neuromuscular Blockade in Strabismus Surgery

The purpose of this study is to determine if inducing a moderate or greater neuromuscular block (TOF count 0-3) when performing a neuromuscular block in pediatric patients aged 3 to 18 years undergoing strabismus surgery under general anesthesia can reduce the incidence of the oculocardiac reflex.

3 - 18 years of age All Phase N/A

Simplify language using AI